What are the key revenue drivers for Eli Lilly in this period?

While the 10-Q doesn't provide specific revenue breakdowns in this excerpt, investors should look to Item 2 (Management's Discussion and Analysis) for details on which therapeutic areas and specific drugs are contributing most significantly to the company's top line, as well as any factors impacting sales of key products.

What is the status of Eli Lilly's drug pipeline?

The filing mentions research and development as a significant investment. Investors should refer to Item 2 (Management's Discussion and Analysis) and potentially Item 8 (Exhibits) for more granular information on the company's late-stage pipeline, clinical trial progress, and potential new drug approvals.

Are there any significant legal or regulatory risks facing Eli Lilly?

Item 1 (Legal Proceedings) and Item 1a (Risk Factors) are crucial sections to review. These will outline any ongoing litigation, regulatory investigations, or other legal challenges that could materially affect the company's financial performance or operations.

How is Eli Lilly managing the impact of potential patent expirations?

The management's discussion and analysis (Item 2) is likely to address strategies for managing patent cliffs, including the introduction of new products or lifecycle management of existing ones. Investors should look for discussions on generic competition and revenue erosion from off-patent drugs.

LLY 10-Q Quarterly Report Q3 FY2010 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 10-Q filing for the period ending September 29, 2010, reveals a company navigating a complex operating environment with both successes and challenges. While the filing indicates progress in certain areas, investors should pay close attention to the interplay of revenue growth, product pipeline developments, and the impact of generic competition. The company's ability to effectively manage its research and development pipeline and defend its market share against upcoming patent expirations will be critical for sustained growth and profitability.

Financial Highlights

47 data points

Beta

Revenue

$5.65B

0.8% Gross Margin

Net Income

$1.30B

0.2% Net Margin

EPS (Diluted)

$1.18

Total Assets

$29.90B

Cash & Equivalents

$5.91B

Free Cash Flow

$1.76B

Financial Statements

Beta

Revenue	$5.65B
Cost of Revenue	$987.60M
Gross Profit	$4.67B
R&D Expenses	$1.22B
SG&A Expenses	$1.69B
Interest Expense	$47.20M
Net Income	$1.30B
EPS (Basic)	$1.18

Key Highlights

1The company is actively managing its product portfolio, which includes both established drugs and promising pipeline candidates.
2Investors should monitor the performance of key products and the impact of upcoming patent cliffs on future revenue streams.
3Research and development expenses remain a significant investment, reflecting Lilly's commitment to innovation and future growth.
4The company is subject to various legal proceedings and regulatory matters, which could have a material impact on its financial condition.
5Management's discussion and analysis will provide insights into operational strategies, market trends, and financial performance drivers.
6The filing provides details on controls and procedures, highlighting the company's commitment to financial reporting integrity.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions